| Title: |
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma |
| Authors: |
Visconti, A; Rossi, N; Deris, H; Lee, KA; Hanic, M; Trbojevic-Akmacic, I; Thomas, AM; Bolte, LA; Bjork, JR; Hooiveld-Noeken, JS; Board, R; Harland, M; Newton-Bishop, J; Harries, M; Sacco, JJ; Lorigan, P; Shaw, HM; de Vries, EGE; Fehrmann, RSN; Weersma, RK; Spector, TD; Nathan, P; Hospers, GAP; Sasieni, P; Bataille, V; Lauc, G; Falchi, M |
| Publisher Information: |
Springer Nature |
| Publication Year: |
2023 |
| Collection: |
Queen Mary University of London: Queen Mary Research Online (QMRO) |
| Subject Terms: |
Melanoma; Immune checkpoint inhibitors; Total serum N-glycomics; Response; Survival |
| Description: |
Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs. Glycosylation affects proteins and lipids’ structure and functions. Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response. Methods We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries. Samples were collected before and during ICI treatment. Results We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone. Conclusion While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response. |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| Relation: |
BMC CANCER; ARTN 166; https://qmro.qmul.ac.uk/xmlui/handle/123456789/96806 |
| DOI: |
10.1186/s12885-023-10511-3 |
| Availability: |
https://qmro.qmul.ac.uk/xmlui/handle/123456789/96806; https://doi.org/10.1186/s12885-023-10511-3 |
| Rights: |
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. ; © The Author(s) 2023. |
| Accession Number: |
edsbas.7AD0408F |
| Database: |
BASE |